Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • AZD0156: Potent, Selective ATM Kinase Inhibitor for DNA D...

    2025-12-17

    AZD0156: Potent, Selective ATM Kinase Inhibitor for DNA Damage Response Modulation

    Executive Summary: AZD0156 (CAS: 1821428-35-6) is a potent, orally bioavailable small-molecule inhibitor targeting ATM kinase, a key mediator of the DNA damage response (APExBIO product page). It exhibits sub-nanomolar inhibitory potency and >1000-fold selectivity versus other PIKK family kinases. Preclinical models show that AZD0156 enhances the efficacy of DNA double-strand break-inducing agents and is under early clinical evaluation for advanced cancers. The compound’s high specificity and utility in checkpoint control modulation make it a valuable research tool (Kostaras et al., 2020). Purity assessments by HPLC/NMR are typically >98%.

    Biological Rationale

    ATM kinase is a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family. It orchestrates the cellular response to DNA double-strand breaks by phosphorylating key substrates involved in DNA repair, cell cycle checkpoints, and apoptosis. Loss or inhibition of ATM function disrupts genomic stability and sensitizes cells to DNA-damaging agents. Selective ATM inhibition is a validated strategy to exploit DNA repair deficiencies in cancer and to enhance the therapeutic index of genotoxic treatments (Kostaras et al., 2020).

    Mechanism of Action of AZD0156

    AZD0156 is a small-molecule inhibitor designed for high affinity and selectivity towards ATM kinase. It binds the ATP-binding pocket of ATM, resulting in inhibition of kinase activity at sub-nanomolar concentrations in cellular assays. This blockade prevents ATM-mediated phosphorylation of downstream effectors such as CHK2, p53, and H2AX, leading to impaired DNA repair and checkpoint activation. AZD0156 demonstrates >1000-fold selectivity for ATM over other PIKK family members (including ATR and DNA-PKcs), thereby minimizing off-target effects (APExBIO).

    Chemically, AZD0156 is a solid compound with a molecular weight of 461.56 g/mol and the formula C26H31N5O3. It is highly soluble in DMSO (≥23.1 mg/mL with gentle warming), moderately soluble in ethanol (≥5.49 mg/mL), and insoluble in water. For laboratory use, it should be stored at -20°C and solutions used promptly to avoid degradation.

    Evidence & Benchmarks

    • AZD0156 inhibits cellular ATM kinase activity with sub-nanomolar potency, as measured by phosphorylation status of canonical substrates (Kostaras et al., 2020, DOI).
    • In preclinical cancer models, oral AZD0156 administration enhances antitumor efficacy when combined with DNA double-strand break-inducing agents (APExBIO, product page).
    • AZD0156 displays >1000-fold selectivity for ATM versus other PIKK kinases in biochemical assays (APExBIO, product page).
    • Purity of supplied AZD0156 (SKU: B7822) is typically >98% by HPLC and NMR (APExBIO, product page).
    • The compound is under early-phase clinical evaluation for safety and preliminary efficacy in advanced cancer patients (Kostaras et al., 2020, DOI).

    This article extends the mechanistic and translational details presented in "AZD0156: Precision ATM Kinase Inhibition for DNA Repair and Metabolic Rewiring" by providing rigorous benchmarks and specific workflow integration guidance, with a focus on selectivity and purity parameters. For a discussion on synthetic lethality and metabolic vulnerabilities, see "AZD0156: Unveiling ATM Inhibition for Synthetic Lethality", which this article updates with current product specifications and clinical progress.

    Applications, Limits & Misconceptions

    AZD0156 is primarily used in research on DNA damage response, cancer biology, and the development of ATM-targeted therapies. Its high selectivity allows for precise dissection of ATM functions without significant cross-reactivity to related kinases. Typical applications include:

    • Enhancing cytotoxicity of DNA double-strand break-inducing agents in cancer cell lines and animal models.
    • Delineating ATM-dependent signaling pathways in checkpoint control and genomic stability.
    • Studying synthetic lethal interactions in tumors with DNA repair deficiencies.
    • Evaluating combinatorial strategies with PARP inhibitors and other DNA repair modulators.

    Common Pitfalls or Misconceptions

    • AZD0156 is not effective in tumors lacking ATM expression or harboring kinase-inactivating ATM mutations.
    • The inhibitor does not target ATR or DNA-PKcs at pharmacologically relevant concentrations; off-target effects are negligible only within prescribed dosing.
    • AZD0156 is not soluble in water; inappropriate solvents may compromise activity or stability.
    • Long-term storage of AZD0156 solutions is not recommended due to degradation; prepare fresh solutions before each use.
    • Current clinical evidence for AZD0156 is limited to early-phase safety and pharmacokinetic studies; efficacy claims in patients are preliminary.

    Workflow Integration & Parameters

    For optimal use, dissolve AZD0156 (SKU: B7822) in DMSO at concentrations up to 23.1 mg/mL with gentle warming. Use ethanol for moderate solubility (≥5.49 mg/mL) if DMSO is incompatible with the assay. The compound should be aliquoted and stored at -20°C to preserve stability. Avoid repeated freeze-thaw cycles and prolonged storage of solutions. For cell-based assays, typical working concentrations range from 1 nM to 1 µM, depending on the sensitivity of the model system (APExBIO).

    All APExBIO-supplied AZD0156 batches include HPLC and NMR purity data for reproducibility. Shipments are sent on Blue Ice to maintain product integrity. Refer to the product page for batch-specific datasheets and material safety information.

    Conclusion & Outlook

    AZD0156 is a state-of-the-art, selective ATM kinase inhibitor enabling advanced research in DNA damage response and cancer therapy. Its robust selectivity and bioavailability profile facilitate mechanistic studies and translational research. Early clinical evaluation is ongoing, with future directions including expanded combinatorial strategies and precision oncology applications. For updated mechanistic insights and metabolic context, see "AZD0156 and the Future of Precision ATM Inhibition in Cancer Research", which this article clarifies by providing dosing, purity, and workflow specifics.